Superiority of Interferon Gamma Assay Over Tuberculin Skin Test for Latent Tuberculosis in Inflammatory Bowel Disease Patients in Brazil

2019 ◽  
Vol 64 (7) ◽  
pp. 1916-1922 ◽  
Author(s):  
Renata F. Amorim ◽  
Eduardo R. C. Viegas ◽  
Antonio José V. Carneiro ◽  
Barbara C. Esberard ◽  
Evelyn S. Chinem ◽  
...  
2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Alok Kumar Mantri ◽  
Priti Meena ◽  
Amarender Singh Puri ◽  
Ajay Kumar ◽  
Sanjeev Sachdeva ◽  
...  

Background. In a country like India, where the prevalence of tuberculosis is very high, the role of screening tools for detection of latent tuberculosis infection (LTBI) like TST and IGRA is still unclear, especially in inflammatory bowel disease (IBD) patients. Our study is aimed at comparing the interferon-gamma release assay (IGRA) and tuberculin skin test (TST) to determine the prevalence of LTBI in IBD patients in the Indian subset of the population. Methods. It was a prospective observational analysis. A total of 257 participants were included in the study. Both TST and IGRA were performed in consecutive patients diagnosed with IBD (131 patients) and in 126 healthy individuals. Both tests were performed on the same day. LTBI diagnosis was considered if any one of TST or IGRA was found to be positive. Results. Out of 131 IBD patients, 121 patients had ulcerative colitis and 10 patients had Crohn’s disease. 29% of the IBD patients and 22% of the control subjects had LTBI. The study demonstrated concordance between TST and IGRA. Agreement test kappa value for IBD patients was 0.656 (CI 0.50-0.81), with a p value of <0.001, suggestive of a fair agreement. Mean IFN-γ release was lower in the immunosuppressed group as compared to non-immunosuppressed individuals ( 0.26 ± 0.17 vs. 0.45 ± 0.07 , p = 0.02 ). Cohen’s kappa coefficient values in IBD cases and control subjects were 0.66 and 0.79, respectively. TST was found to be negatively correlated to BMI. Conclusion. Agreement between TST and IGRA was fair in IBD patients. For LTBI screening in IBD patients, TST and IGRA are complementary methods.


2020 ◽  
Vol 18 (3) ◽  
pp. 306-314
Author(s):  
Saad Alrajhi ◽  
Pascale Germain ◽  
Myriam Martel ◽  
Peter Lakatos ◽  
Talat Bessissow ◽  
...  

Background/Aims: Latent tuberculosis screening is mandatory prior to initiating anti-tumor necrosis factor (anti-TNF) medications. Guidelines recommend interferon-gamma release assays (IGRA) as first line screening method for the general population. Studies provided conflicting evidence on IGRA and tuberculin skin test (TST) performance in inflammatory bowel disease (IBD) patients. We assessed test concordance and the effects of immunosuppression on their performance in IBD patients.Methods: We searched MEDLINE, Embase and Cochrane databases (2011–2018) for studies testing TST and IGRA in IBD. Primary outcome was TST and IGRA concordance. Secondary outcomes were effects of immunosuppressive therapy on performance. Immunosuppression defined as either steroids, thiopurine, methotrexate or cyclosporine use. We used the pooled random effects model to adjust for heterogeneity analyzed using (I<sup>2</sup>–Q statistics). We compared the fixed model to exclude smaller study effects.Results: Sixteen studies (2,488 patients) were included. Pooled TST and IGRA concordance was 85% (95% confidence interval [CI], 81%–88%; <i>P</i>=0.01). Effects of immunosuppression were reported in 8 studies (814 patients). The odds ratio of testing positive by IGRA decreased to 0.57 if immunosuppressed (95% CI, 0.31–1.03; <i>P</i>=0.06). The odds ratio of testing positive by TST if immunosuppressed was 1.14 (95% CI, 0.61–2.12; <i>P</i>=0.69). The fixed model yielded similar results, however the negative effect of immunosuppression on IGRA reached statistical significance (<i>P</i>=0.01).Conclusions: While concordance was 85% between TST and IGRA, the performance of IGRA seems to be negatively affected by immunosuppression. Given the importance of detecting latent tuberculosis prior to anti-TNF initiation, further randomized controlled trials comparing the performance of TST and IGRA in IBD patients are needed.


2016 ◽  
Vol 48 (12) ◽  
pp. 1438-1443 ◽  
Author(s):  
Cândida Abreu ◽  
Francisco Almeida ◽  
Rita Ferraz ◽  
Claúdia Camila Dias ◽  
António Sarmento ◽  
...  

2017 ◽  
Vol 152 (5) ◽  
pp. S611
Author(s):  
Carlos Taxonera Samso ◽  
Angel Ponferrada ◽  
Fernando Bermejo ◽  
Javier P. Gisbert ◽  
Sabino Riestra Menendez ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document